Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Stop me if you’ve heard this one before.
Half of people with worse liver function responded well to immunotherapy.
First new treatment in two decades for uncommon type of lung cancer.
Multiple immune cell types must be present in tumors for checkpoint inhibitor therapies to be effective.
We’re asking you to show how you harness your unique inner power to rise up against cancer.
First-line immunotherapy combo improved progression-free survival in people with highly mutated lung tumors.
Immunotherapy combo provided durable benefit for people with advanced colorectal cancer.
The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.
Imfinzi tripled progression-free survival in previously treated patients with inoperable lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.